Insys Therapeutics Reports Second Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Boeing nears approval of 737 MAX anti-ice fix, paving way for deliveries
Insys Therapeutics (INSY) Misses Q2 EPS by 1c
August 3, 2016 6:55 AM EDTInsys Therapeutics (NASDAQ: INSY) reported Q2 EPS of $0.06, $0.01 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $67.1 million versus the consensus estimate of $66.9 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
... More